ICRA: In FY23, the retail NBFCs to probably witness growth in business
Wed, Mar 30, 2022 4:56 PM

ICRA: In FY23, the retail NBFCs to probably witness growth in business

A Flip by Shambhavi
Get it on Google Play
Retail non-banking finance companies will probably see an imminent improvement in business, with growth in assets under management. As per the rating agency, ICRA, most entities project growth to pick up in FY2023 with a large number or proportion of entities expecting to grow at 10-15%. Within non-banks, Micro Finance Institutions aim for much higher growth (upwards of 20%).

More great flips

Muthoot Finance's arm Belstar Microfinance files Rs 1,300-cr IPO papers

Muthoot Finance's arm Belstar Microfinance files Rs 1,300-cr IPO papers

Muthoot Finance’s microfinance arm, Belstar Microfinance Ltd, on Sunday filed preliminary papers with capital markets regulator Sebi to raise Rs 1,300 crore through an initial public offering (IPO). The Chennai-based entity’s IPO is a combination of fresh issue of equity shares worth Rs 1,000 crore and an offer-for-sale (OFS) of Rs 300 crore by investor shareholders, according to the DRHP.

Open Flip
Where to look for new opportunities in this expensive market?

Where to look for new opportunities in this expensive market?

It is no secret that, on an aggregate basis, broader space is trading at an extremely expensive multiple (over 33 times on a trailing basis for BSE Small-cap index). In an expensive market, hidden opportunities exist despite high valuations. AMCs offer potential post sector rerating. Discounted prospects like UTI and ABSL present favorable entry points for investors eyeing long-term growth.

Open Flip
Cipla, Glenmark recall drugs from US market: USFDA

Cipla, Glenmark recall drugs from US market: USFDA

Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), a New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution.

Open Flip

Join our Smart Investment Community

More than 1 Million users are using FlipItMoney to stay updated about the business and finance world! Join FlipItMoney now and take smart investment decisions!
Icon